Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Transforming NCI Cancer Clinical Trials - NCI
Next Steps for KRAS Inhibitors Focus on Tackling Resistance
Leukemia Drug Trial Reveals How Cancer Cells Resist Therapy
Treatment - Cancer Currents Blog - NCI
National Cancer Institute (NCI) on LinkedIn: Cancer Grand
Treatment National Cancer Institute
Primary Endpoint Met for Revumenib in Patients with AML and ALL
Tana Takacova posted on LinkedIn
Revumenib trial meets complete remission endpoint for acute
de
por adulto (o preço varia de acordo com o tamanho do grupo)
